Document is current
Any future updates will be listed below
-
Authors
Cottereaux, Céline https://orcid.org/0000-0002-4883-3154
Lepage, May-Linda https://orcid.org/0009-0007-7533-1778
Parent, Isabelle https://orcid.org/0000-0002-7947-0544
Colli, Maikel https://orcid.org/0000-0002-2200-4761
Van de Water, An https://orcid.org/0000-0002-2802-3883
Lagoutte, Emilie https://orcid.org/0000-0002-7142-1238
David, Christelle https://orcid.org/0009-0003-2618-8697
Van Balen, Maarten https://orcid.org/0009-0005-3881-5832
Cosson, Adrien https://orcid.org/0000-0003-1637-9660
Blanque, Roland https://orcid.org/0000-0001-6578-4676
Shoji, Kenji https://orcid.org/0000-0002-8137-2521
Jans, Mia https://orcid.org/0009-0003-4902-7677
Furio, Laetitia https://orcid.org/0009-0009-0914-926X
Van der Plas, Steven https://orcid.org/0000-0003-3171-229X
Brys, Reginald https://orcid.org/0000-0002-3415-7124
Amantini, David https://orcid.org/0000-0002-6758-1861
Galien, René https://orcid.org/0000-0003-4199-9263
- License Information
-
More Information
Article History
Received: 24 December 2025
Revised: 31 March 2026
Accepted: 29 April 2026
First Online: 16 May 2026
Declarations
:
: Clinical studies NCT04097938 and NCT04736927 were approved by the OLV Ziekenhuis Ethisch Comité (Belgium; approval number 2019/065) and the Wales Research Ethics Committee 2 (approval number 20/WA/0335), respectively. The studies complied with all relevant ethical regulations, and all participants provided written informed consent to participate in these studies.
: Not applicable.
: Céline Cottereaux, May-Linda Lepage, Isabelle Parent, Adrien Cosson, and Roland Blanque were employees of Galapagos SASU at the time of the study and are now employees of NovAliX. Maikel Colli, An Van de Water, Maarten Van Balen, and Mia Jans are employees and shareholders of Galapagos NV. Emilie Lagoutte and Laetitia Furio were employees of Galapagos SASU at the time of the study and are now employees of Calida Therapeutics. Christelle David was an employee of Galapagos SASU at the time of the study and is now an employee of ISS AG. Kenji Shoji was an employee of Galapagos SASU at the time of the study and is now an employee of Oncodesign Precision Medicine. Steven Van der Plas was an employee of Galapagos NV at the time of the study and is now an employee of iTeos Therapeutics. Reginald Brys was an employee of Galapagos NV at the time of the study and is now an employee of Agomab Therapeutics. David Amantini was an employee of Galapagos SASU at the time of the study. René Galien was an employee of Galapagos SASU at the time of the study.
